SUPPLY OF BOTULISM ANTITOXIN HEPTEVALENT (HBAT)

Concepts

• bristol
• immunoglobulins
• emergent biosolutions canada inc
• defence equipment and support
• uk ministry of defence
• supply of botulism antitoxin heptevalent
• supply of heptavalent botulism antitoxin
• antitoxin serotypes a-g
• botulism
• treatment of botulism

Location

Description

The Chemical, Biological, Radiological and Nuclear (CBRN) team, part of Defence Equipment and Support (DE&S) organisation within the UK Ministry of Defence (MOD), intends to place a contract with Emergent Biosolutions Canada Inc for the supply of Heptavalent Botulism Antitoxin (HBAT) for a period of 10 years (5 + 5 Option Years) with an estimated value of £20m. This is necessary to ensure maintenance of the capability with an acceptable stockholding level.

Total Quantity or Scope

The Chemical, Biological, Radiological and Nuclear (CBRN) team, part of Defence Equipment and Support (DE&S) organisation within the UK Ministry of Defence (MOD), intends to place a contract with Emergent for the supply of Heptavalent Botulism Antitoxin (HBAT) for a period of 10 years (5 + 5 Option Years) with an estimated value of £20M+. … Due to the estimated contract value and on the basis that it is to be placed directly with Emergent Biosolutions Canada Inc, the contract will be a Qualifying Defence Contract (QDC) and shall comply with the Single Source Contract Regulations (SSCR) 2014. It is considered that this contract can be awarded using the negotiated procedure without prior publication of a contract notice, pursuant to Public Contracts Regulations 2015; where “Regulation 32 (2)(b)(ii) allows you to use the Negotiated procedure without Prior Publication when the exclusivity is due to technical reasons”. Summary of the Technical Reason: Emergent Biosolutions Canada Inc are currently the only licensed manufacturer for HBAT (BAT®) which provides antitoxin serotypes A-G for treatment of Botulism worldwide. This product is therefore the only product which provides the full capability to Defence. Additional information: Due to the limitations of the character limit at II 2.4) Description — it is not possible to enter the full details of the single source justification, for full details of the reasoning, please email Tamika.Kelly116@mod.gov.uk so that it can be forwarded to you.

Award Detail

Renewal Options

5 Optional Years

Award Criteria

CPV Codes

• 33651520 - Immunoglobulins

Indicators

• Options are available.

Legal Justification

It is considered that this contract can be awarded using the negotiated procedure without prior publication of a contract notice, pursuant to Public Contracts Regulations 2015; where “Regulation 32 (2)(b)(ii) allows you to use the Negotiated procedure without Prior Publication when the exclusivity is due to technical reasons”. Summary of the Summary of the Technical Reason: Emergent Biosolutions Canada Inc are currently the only licensed manufacturer for HBAT (BAT®) which provides antitoxin serotypes A-G for treatment of Botulism worldwide. This product is therefore the only product which provides the full capability to Defence.

Other Information

** PREVIEW NOTICE, please check Find a Tender for full details. **